Literature DB >> 24374000

A high-performance liquid chromatography assay for Dyrk1a, a Down syndrome-associated kinase.

Linh C Bui1, Laure Tabouy1, Florent Busi1, Jean-Marie Dupret1, Nathalie Janel1, Chris Planque1, Jean-Maurice Delabar1, Fernando Rodrigues-Lima2, Julien Dairou3.   

Abstract

Down syndrome is the most common aneuploidy. It is caused by the presence of an extra copy of chromosome 21. Several studies indicate that aberrant expression of the kinase Dyrk1a (dual-specificity tyrosine phosphorylation-regulated kinase 1a) is implicated in Down syndrome, in particular in the onset of mental retardation. Moreover, elevated Dyrk1a activity may also be a risk factor for other neurodegenerative disorders such as Alzheimer's disease. Over the past years, Dyrk1a has appeared as a potential drug target. Availability of sensitive and quantitative enzyme assays is of prime importance to understand the role of Dyrk1a and to develop specific inhibitors. Here, we describe a new method to measure Dyrk1a activity based on the separation and quantification of specific fluorescent peptides (substrate and phosphorylated product) by high-performance liquid chromatography (HPLC). Kinetic and mechanistic analyses using well-known inhibitors of Dyrk1a confirmed the reliability of this approach. In addition, this assay was further validated using brain extracts of mice models expressing different copies of the Dyrk1a gene. Our results indicate that this novel Dyrk1a assay is simple, sensitive, and specific. It avoids the use of radioactivity-based approaches that, until now, have been widely employed to measure Dyrk1a activity.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Down syndrome; Dyrk1a; Enzyme assay; HPLC; Kinase

Mesh:

Substances:

Year:  2013        PMID: 24374000     DOI: 10.1016/j.ab.2013.12.024

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  9 in total

1.  High-performance liquid chromatography-based method to evaluate kinetics of glucosinolate hydrolysis by Sinapis alba myrosinase.

Authors:  Kayla J Vastenhout; Ruthellen H Tornberg; Amanda L Johnson; Michael W Amolins; Jared R Mays
Journal:  Anal Biochem       Date:  2014-07-25       Impact factor: 3.365

2.  Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.

Authors:  Megan Stringer; Irushi Abeysekera; Jared Thomas; Jonathan LaCombe; Kailey Stancombe; Robert J Stewart; Karl J Dria; Joseph M Wallace; Charles R Goodlett; Randall J Roper
Journal:  Physiol Behav       Date:  2017-05-03

3.  A RP-UFLC Assay for Protein Tyrosine Phosphatases: Focus on Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2).

Authors:  Romain Duval; Linh-Chi Bui; Jérémy Berthelet; Julien Dairou; Cécile Mathieu; Fabien Guidez; Jean-Marie Dupret; Jan Cools; Christine Chomienne; Fernando Rodrigues-Lima
Journal:  Sci Rep       Date:  2015-06-04       Impact factor: 4.379

4.  An ELISA DYRK1A non-radioactive assay suitable for the characterization of inhibitors.

Authors:  Yong Liu; Tatyana Adayev; Yu-Wen Hwang
Journal:  F1000Res       Date:  2017-01-13

5.  Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer's disease.

Authors:  N Janel; P Alexopoulos; A Badel; F Lamari; A C Camproux; J Lagarde; S Simon; C Feraudet-Tarisse; P Lamourette; M Arbones; J L Paul; B Dubois; M C Potier; M Sarazin; J M Delabar
Journal:  Transl Psychiatry       Date:  2017-06-20       Impact factor: 6.222

6.  DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives.

Authors:  Fernanda Neumann; Stéphanie Gourdain; Christelle Albac; Alain D Dekker; Linh Chi Bui; Julien Dairou; Isabelle Schmitz-Afonso; Nathalie Hue; Fernando Rodrigues-Lima; Jean M Delabar; Marie-Claude Potier; Jean-Pierre Le Caër; David Touboul; Benoît Delatour; Kevin Cariou; Robert H Dodd
Journal:  Sci Rep       Date:  2018-02-12       Impact factor: 4.379

7.  Prenatal treatment with EGCG enriched green tea extract rescues GAD67 related developmental and cognitive defects in Down syndrome mouse models.

Authors:  Benoit Souchet; Arnaud Duchon; Yuchen Gu; Julien Dairou; Claire Chevalier; Fabrice Daubigney; Valérie Nalesso; Nicole Créau; Yuejin Yu; Nathalie Janel; Yann Herault; Jean Maurice Delabar
Journal:  Sci Rep       Date:  2019-03-08       Impact factor: 4.379

8.  Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice.

Authors:  Benoît Souchet; Mickael Audrain; Jean Marie Billard; Julien Dairou; Romain Fol; Nicola Salvatore Orefice; Satoru Tada; Yuchen Gu; Gaelle Dufayet-Chaffaud; Emmanuelle Limanton; François Carreaux; Jean-Pierre Bazureau; Sandro Alves; Laurent Meijer; Nathalie Janel; Jérôme Braudeau; Nathalie Cartier
Journal:  Acta Neuropathol Commun       Date:  2019-03-18       Impact factor: 7.801

9.  Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with Fontup® Dietary Supplement: Role of Green Tea Catechins.

Authors:  Yuchen Gu; Gautier Moroy; Jean-Louis Paul; Anne-Sophie Rebillat; Mara Dierssen; Rafael de la Torre; Cécile Cieuta-Walti; Julien Dairou; Nathalie Janel
Journal:  Int J Mol Sci       Date:  2020-02-19       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.